Bausch Health Cos Inc. (NYSE:BHC) Receives Consensus Rating of "Reduce" from Analysts

Key Points

• Analysts rate Bausch Health “Reduce”: Of seven analysts, one recommends selling and six recommend holding. The average 12-month price target is $8.00.
• Quarterly results exceeded expectations: Bausch Health reported adjusted earnings of $1.26 per share versus the $0.96 consensus estimate, while revenue reached $2.83 billion against expectations of $2.59 billion.
• Shares remain financially challenged: BHC opened at $6.42, with a negative net margin of 10.12% and negative return on equity of 561.95%; institutional investors own 78.65% of the stock.

Shares of Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) have received a consensus recommendation of "Reduce" from the seven analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $8.00.

BHC has been the topic of several analyst reports. Zacks Research raised Bausch Health Cos from a "strong sell" rating to a "hold" rating in a report on Thursday. Weiss Ratings raised Bausch Health Cos from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday, July 31st. Jefferies Financial Group upgraded Bausch Health Cos to a "hold" rating in a research report on Wednesday, July 22nd. Wall Street Zen raised shares of Bausch Health Cos from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 1st. Finally, Royal Bank Of Canada decreased their target price on shares of Bausch Health Cos from $10.00 to $9.00 and set a "sector perform" rating for the company in a research note on Monday, April 27th.

Bausch Health Cos Trading Down 0.3%

NYSE BHC opened at $6.42 on Monday. Bausch Health Cos has a 1 year low of $4.33 and a 1 year high of $8.00. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.44 and a quick ratio of 1.08. The company has a market capitalization of $2.40 billion, a PE ratio of -2.17 and a beta of 0.38. The company has a fifty day moving average of $5.36 and a 200 day moving average of $5.46.

Bausch Health Cos (NYSE:BHC - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.30. The company had revenue of $2.83 billion for the quarter, compared to the consensus estimate of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. Research analysts forecast that Bausch Health Cos will post 4.35 earnings per share for the current year.

Insiders Place Their Bets

In other Bausch Health Cos news, insider Aimee J. Lenar sold 36,827 shares of Bausch Health Cos stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total value of $258,893.81. Following the completion of the transaction, the insider owned 334,853 shares of the company's stock, valued at approximately $2,354,016.59. The trade was a 9.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company's stock.

Institutional Trading of Bausch Health Cos

Several institutional investors have recently bought and sold shares of the business. Tidal Investments LLC grew its stake in shares of Bausch Health Cos by 2.6% in the second quarter. Tidal Investments LLC now owns 50,131 shares of the company's stock worth $334,000 after acquiring an additional 1,276 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in shares of Bausch Health Cos by 14.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company's stock valued at $98,000 after acquiring an additional 1,812 shares in the last quarter. Jones Financial Companies Lllp acquired a new stake in shares of Bausch Health Cos in the second quarter valued at $148,000. Pictet Asset Management Holding SA boosted its holdings in Bausch Health Cos by 4.1% in the first quarter. Pictet Asset Management Holding SA now owns 54,169 shares of the company's stock valued at $292,000 after purchasing an additional 2,114 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in Bausch Health Cos by 2.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company's stock valued at $690,000 after purchasing an additional 2,552 shares during the period. 78.65% of the stock is owned by institutional investors and hedge funds.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source